Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S040 - Systemic Therapies for Dermatologists: A Comprehensive Review and Update

Sunday, February 18; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Utilize newer systemic agents available for psoriasis, atopic dermatitis and alopecia areata.
  • Discuss the risks and benefits of new systemic agents available for cancers such as melanoma and basal cell carcinoma.
  • Optimize management of patients with Stevens Johnson syndrome/toxic epidermal necrosis.

Description

We are in an exciting time with the development of new dermatologic agents, and not just for psoriasis. In this session we will look at some of the newest systemic agents that are now available and being used for alopecia areata, atopic dermatitis, psoriasis, melanoma and basal cell carcinoma. We will also revisit an older agent that may have found a new use in SJS/TEN.

Disclosures

  • Chang, Anne Lynn S., MD: Galderma Laboratories, L.P. – I(Grants/Research Funding); Genentech, Inc. – I(Grants/Research Funding); Merck & Co., Inc – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Nuskin – I(Grants/Research Funding);
  • Nunley, Julia R., MD: no financial relationships exist with commercial interests.
  • Owen, Cindy, MD: no financial relationships exist with commercial interests.
  • Salkey, Kimberly Scott, MD: no financial relationships exist with commercial interests.
  • Simpson, Eric Lawrence, MD: AbbVie – C(Fees); Eli Lilly and Company – I(Grants/Research Funding); GlaxoSmithKline – C(Fees); Medimmune – I(Grants/Research Funding); Novartis – I(Grants/Research Funding); Pfizer Inc. – C(Fees), I(Grants/Research Funding); Regeneron – C(Fees), I(Grants/Research Funding); Roivant Sciences – I(Grants/Research Funding); Tioga Pharmaceuticals, Inc. – I(Grants/Research Funding); Vanda Pharmaceuticals Inc. – I(Grants/Research Funding);
  • Tsao, Hensin, MD, PhD: Epiphany Dermatology – A(H); Massachusetts General Hospital – E(S); Relay Therapeutics – I(Grants/Research Funding);
  • Van Voorhees, Abby S., MD: AbbVie – C(H); Allergan, Inc – A(H); Celgene Corporation – C(H), I(Grants/Research Funding); Derm Tech International – C(H); Dermira – A(H); Merck & Co., Inc – O(OB); Novartis – A(H), C(H); WebMD – C(H);
Schedule
Sunday, February 18
1:00 PM
Dr. Simpson / Update for atopic dermatitis
1:30 PM
Dr. Van Voorhees / Update for psoriasis
2:00 PM
Dr. Tsao / Update for melanoma
2:30 PM
Dr. Owen / Update for SJS/TEN
3:00 PM
Dr. Salkey / Up date for alopecia areata
3:00 PM
Dr. Chang / Update for basal cell carcinoma
Event Details
  • Date
    Sunday, February 18
  • Time
    1:00 PM - 4:00 PM
  • Location
    Room 5A
  • CME Credits
    3.00
  • Type
    New
Directors/Co-Directors
  • Julia R. Nunley, MD, FAAD
Speakers
  • Abby S. Van Voorhees, MD, FAAD
  • Anne Lynn S. Chang, MD, FAAD
  • Cindy Owen, MD, FAAD
  • Eric Lawrence Simpson, MD, FAAD
  • Hensin Tsao, MD, PhD, FAAD
  • Kimberly Scott Salkey, MD, FAAD